Welcome to our dedicated page for Sintx Technologies SEC filings (Ticker: SINT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SINTX Technologies, Inc. filings document an advanced ceramics and biomaterials issuer focused on silicon nitride medical technologies, including formal disclosures on operating results, regulatory communications, capital formation, and governance. Recent Form 8-K reports cover quarterly financial results and Regulation FD disclosures tied to FDA 510(k) activity for silicon nitride foot and ankle medical devices.
The company’s SEC record also includes an at-the-market common stock offering agreement, officer appointment and executive compensation disclosures, and a definitive proxy statement for annual meeting voting. These filings describe board and stockholder matters, material agreements, common stock issuance mechanics, and formal disclosure topics connected to SINTX’s medical-device commercialization and biomaterials platform.
Sintx Technologies director Mark Lewis Anderson bought additional company stock in the open market. On February 18, 2026, he purchased 3,000 shares of Sintx Technologies common stock at a price of $3.02 per share. After this transaction, his directly held stake increased to 18,000 shares.
SINTX Technologies reported a leadership change and new executive employment terms. Effective March 16, 2026, Eric Olson will stop serving as President but will remain Chairman of the Board and Chief Executive Officer. On the same date, Ryan Elmore will become President and report to the CEO.
Elmore brings over 20 years of leadership experience in medical device and life sciences businesses, including senior commercial and international roles at Invibio, a division of Victrex plc. His executive employment agreement includes a base salary of $375,000 per year, a target annual cash bonus of 35% of base salary (with his first-year bonus guaranteed), and a $100,000 sign-on bonus payable at the start of employment.
Upon starting, he will also receive restricted stock units with a grant date value of $300,000, with 20% vesting immediately and the rest vesting in equal installments over 24 months, subject to continued employment, plus eligibility for additional equity awards tied to international business milestones. If his employment is terminated by the company without cause or by him for good reason, he is entitled to accrued compensation, a cash severance equal to two times his base salary plus target bonus, and up to 24 months of continued health coverage or equivalent cash payments, with enhanced protections in certain change in control situations.
Sintx Technologies, Inc. reported an equity award to its Chief Financial Officer, Kevin Trask. On February 6, 2026, he was granted 60,000 restricted stock units (RSUs) under the company’s 2025 Equity Incentive Plan, at a stated price of $0.00 per unit.
Each RSU represents the right to receive one share of Sintx common stock upon vesting. 20% of the award vested immediately, with the remaining RSUs vesting in additional 20% increments every six months thereafter. Following this grant, Trask directly holds 100,000 derivative securities in the form of RSUs.
Sintx Technologies reported an insider equity award for its Chairman, President and CEO, Eric K. Olson. On February 6, 2026, he was granted 100,000 restricted stock units (RSUs) at a price of $0.00 per unit under the company’s 2025 Equity Incentive Plan.
Each RSU represents the right to receive one share of common stock upon vesting. 20% vested immediately, with the remaining units vesting in 20% increments every six months. Following this grant, Olson directly holds 160,000 derivative securities in the form of RSUs.
Sintx Technologies, Inc. reported that Chief Investment Officer and director Gregg R. Honigblum received an award of 75,000 restricted stock units (RSUs) on February 6, 2026 under the company’s 2025 Equity Incentive Plan.
Each RSU represents the right to receive one share of common stock upon vesting. 20% of the grant vested immediately, with the remaining RSUs vesting in additional 20% installments every six months. Following this award, Honigblum beneficially owned 133,000 derivative securities tied to Sintx common stock in direct ownership.
Sintx Technologies director and Chief Investment Officer Kevin Ontiveros reported significant increases in his ownership of the company’s common stock. On 12/05/2025, he made a series of open-market purchases, each for 5,000 shares of common stock, at prices ranging from $3.77 to $4.07 per share. After these purchases, his directly held stake rose to 139,000 shares.
On the same date, he also received an additional 53,867 common shares at a price of $0.00, described as an issuance incident to the vesting of a Restricted Stock Unit Award. Following this vesting, his directly owned common stock position increased further to 192,867 shares, highlighting both active open-market buying and equity compensation-based ownership growth.
SINTX Technologies furnished an 8-K announcing financial results for the quarter ended September 30, 2025. The results were released via a press release furnished as Exhibit 99.1, which also discusses the company’s use of a non-GAAP financial measure.
The information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and is not incorporated by reference except as expressly stated. The Item 2.02 information is also included under Item 7.01 by reference.
SINTX Technologies filed its Q3 2025 10‑Q, reporting total revenue of $208k (down 74% year over year) and a net loss of $3.539M. Gross profit was $93k, with operating expenses of $3.448M driven by R&D $1.264M and G&A $2.102M. Cash and cash equivalents were $6.250M as of September 30, 2025.
The company continued shifting away from low‑margin OEM work toward proprietary silicon nitride medical devices. It received FDA 510(k) clearance in October 2025 for the SiNAPTIC Foot & Ankle Osteotomy Wedge System, with revenue expected to begin in the first half of 2026. Q3 also included an inducement in which holders exercised warrants for ~$3.8M in gross proceeds, creating a $6.7M deemed dividend.
SINTX strengthened liquidity with a $6.41M at‑the‑market facility established in October 2025 and expects ~$950k savings from subleasing the armor facility. Management states no significant uncertainty regarding its ability to continue as a going concern through at least November 12, 2026. Shares outstanding were 3,851,956 as of November 7, 2025.
Sintx Technologies (SINT) insider activity: A company director and Chief Investment Officer reported open‑market purchases on 11/07/2025. The filer bought 5,000 shares at $3.20 and 5,000 shares at $3.18, increasing beneficial ownership to 74,000 shares, held directly.
SINTX Technologies (Nasdaq: SINT) filed a resale registration covering up to 1,741,539 shares of common stock to be offered by selling stockholders. The registered shares consist of 1,649,147 common warrant shares and 92,392 placement agent warrant shares issued in connection with a February 2025 private placement and an inducement letter dated September 8, 2025.
The company is not selling any shares in this prospectus and will not receive proceeds from selling stockholder resales. SINTX would receive up to approximately $8.3 million only if the warrants are exercised for cash; stated exercise prices include $4.79 for the common warrants and $4.3844 and $4.3125 for the placement agent warrants. Any cash received from exercises will be used for working capital and general corporate purposes.
Shares may be sold by the holders at market, fixed, related, or negotiated prices through various methods described in the plan of distribution. Shares outstanding were 3,683,989 as of October 20, 2025; this is a baseline figure, not the amount being registered. The last reported SINT price was $3.25 on October 22, 2025.